Tan Ying, Pan Yuesong, Liu Liping, Wang Yilong, Zhao Xingquan, Wang Yongjun
a Department of Neurology , Beijing Tiantan Hospital, Capital Medical University , Beijing , China.
b China National Clinical Research Center for Neurological Diseases , Beijing , China.
Neurol Res. 2017 Jun;39(6):484-491. doi: 10.1080/01616412.2017.1322804. Epub 2017 May 5.
Limited data are available on secondary preventive therapy use and patient outcomes after acute minor ischemic stroke in China. This study investigated secondary prevention strategies and outcomes up to 1 year after minor ischemic stroke.
Patients from the China National Stroke Registry experienced a minor ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score ≤5) and admitted to hospital within 24 hours of symptom onset were included. One-year rates of recurrent stroke, stroke-related disability, and all-cause death were evaluated. Risk factors associated with 1-year stroke recurrence were examined in a multivariate model. The secondary prevention strategies in the acute phase were evaluated as combination of secondary prevention medication classes and the medications used in 1 year follow-up were examined.
The study included 1913 patients who had experienced acute minor ischemic stroke (mean age: 65.1 years; 67.3% men; mean NIHSS score: 2.5). Rates of recurrent stroke, disability, and death were 13.2, 17.0, and 6.3% at 1 year, respectively. History of hypertension, ischemic stroke, transient ischemic attack, and atrial fibrillation were independent predictors of one-year stroke recurrence. Rate of 1 year all-cause death in patients with triple combined therapy in acute phase was 4.1%, whereas in patients with none was 14.5%. At 1 year, only half patients continued the secondary prevention medications.
Outcomes in individuals in China who had experienced acute minor stroke were unfavorable, underscoring the importance of early, sustained preventive therapy in this patient population. Combination of secondary prevention medication classes was associated with a lower risk of death.
在中国,关于急性轻度缺血性卒中后二级预防治疗的使用情况及患者预后的数据有限。本研究调查了轻度缺血性卒中后长达1年的二级预防策略及预后情况。
纳入来自中国国家卒中登记系统的患者,这些患者发生轻度缺血性卒中(美国国立卫生研究院卒中量表[NIHSS]评分≤5)且在症状发作后24小时内入院。评估复发性卒中、卒中相关残疾和全因死亡的1年发生率。在多变量模型中检查与1年卒中复发相关的危险因素。评估急性期二级预防策略,包括二级预防药物类别组合,并检查1年随访中使用的药物。
该研究纳入了1913例发生急性轻度缺血性卒中的患者(平均年龄:65.1岁;男性占67.3%;平均NIHSS评分:2.5)。1年时复发性卒中、残疾和死亡的发生率分别为13.2%、17.0%和6.3%。高血压病史、缺血性卒中、短暂性脑缺血发作和心房颤动是1年卒中复发的独立预测因素。急性期接受三联联合治疗的患者1年全因死亡率为4.1%,而未接受治疗的患者为14.5%。1年时,只有一半的患者继续服用二级预防药物。
中国急性轻度卒中患者的预后不佳,这凸显了对该患者群体进行早期、持续预防性治疗的重要性。二级预防药物类别组合与较低的死亡风险相关。